We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-0.34%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
-$21.2M
Cap. Flow
+$40.7M
Cap. Flow %
1.55%
Top 10 Hldgs %
39.68%
Holding
190
New
18
Increased
27
Reduced
27
Closed
13

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$47.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$18.8M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$18M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.7M
5
PFE icon
Pfizer
PFE
+$13.7M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$47.2M
2
SYK icon
Stryker
SYK
+$24.6M
3
ZBH icon
Zimmer Biomet
ZBH
+$24M
4
HUM icon
Humana
HUM
+$20.2M
5
UNH icon
UnitedHealth
UNH
+$17.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.54%
2 Real Estate 2.01%
3 Industrials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
51
Neurocrine Biosciences
NBIX
$16.9B
$11.4M 0.44%
112,908
– –
XBI icon
52
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$11.3M 0.43%
147,677
– –
GH icon
53
Guardant Health
GH
$21.3B
$11.1M 0.42%
472,184
– –
RLYB icon
54
Rallybio
RLYB
$84.6M
$9.86M 0.38%
215,883
– –
AVTR icon
55
Avantor
AVTR
$9.25B
$9.71M 0.37%
459,488
– –
KRTX
56
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$9.71M 0.37%
53,452
– –
TVTX icon
57
Travere Therapeutics
TVTX
$5.11B
$9.41M 0.36%
418,520
– –
ITCI
58
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.33M 0.36%
172,371
– –
LH icon
59
Labcorp
LH
$24.9B
$9.19M 0.35%
46,609
-4,772
-9% -$982K
APLS
60
DELISTED
Apellis Pharmaceuticals
APLS
$8.91M 0.34%
135,124
+68,698
+103% +$3.96M
ALKS icon
61
Alkermes
ALKS
$8.31B
$8.73M 0.33%
309,613
– –
ZBH icon
62
Zimmer Biomet
ZBH
$18.8B
$8.7M 0.33%
67,356
-191,512
-74% -$24M
OHI icon
63
Omega Healthcare
OHI
$14.7B
$8.4M 0.32%
306,433
– –
CYTK icon
64
Cytokinetics
CYTK
$10.4B
$7.71M 0.29%
219,025
+143,886
+191% +$5.87M
DNLI icon
65
Denali Therapeutics
DNLI
$3.67B
$7.48M 0.28%
324,829
+52,309
+19% +$1.44M
CVS icon
66
CVS Health
CVS
$134B
$6.96M 0.26%
93,621
– –
SNY icon
67
Sanofi
SNY
$103B
$6.72M 0.26%
123,454
– –
LNTH icon
68
Lantheus
LNTH
$6.59B
$6.56M 0.25%
79,495
-263,377
-77% -$17M
LTC
69
LTC Properties
LTC
$1.99B
$6.4M 0.24%
182,293
– –
A icon
70
Agilent Technologies
A
$39.5B
$5.98M 0.23%
43,191
– –
STE icon
71
Steris
STE
$22.7B
$5.94M 0.23%
31,072
+14,403
+86% +$2.78M
SBRA icon
72
Sabra Healthcare REIT
SBRA
$5.2B
$5.87M 0.22%
510,660
– –
VECT
73
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$5.87M 0.22%
682,834
-54,870
-7% -$452K
NTLA icon
74
Intellia Therapeutics
NTLA
$1.5B
$5.75M 0.22%
154,269
– –
MDRX
75
DELISTED
Veradigm Inc. Common Stock
MDRX
$5.59M 0.21%
428,580
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Tekla Capital Management held 190 positions worth $2.63B, down 0.8% from $2.65B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q1 2023 filing shows 18 new, 27 increased, 27 reduced and 13 closed positions. Its largest new stake was Exelixis: 726,639 shares worth $14.1M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $47.2M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2023 buy was Exelixis: 726,639 shares worth $14.1M.
  • Tekla Capital Management added most to Elevance Health in Q1 2023, an estimated $47.3M increase.
  • Tekla Capital Management's biggest Q1 2023 reduction was Stryker, cutting an estimated $24.6M.
  • Tekla Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $47.2M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.63B portfolio in Q1 2023.
  • Tekla Capital Management opened 18 new positions and closed 13 in Q1 2023.
  • Tekla Capital Management's portfolio value fell 0.8% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q1 2023, filed 10 May 2023.